Fast track — ArticlesTransmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial
Introduction
Standard treatments for angina pectoris are effective for most patients. Some patients with advanced disease, however, become less responsive to medication but are not candidates for percutaneous transluminal coronary angioplasty or coronary-artery bypass grafting because the atherosclerotic lesions are too diffuse. These patients have frequent angina, limited exercise tolerance, and poor quality of life. Transmyocardial revascularisation (TMR) was developed to treat such patients.1 TMR is a surgical procedure that uses a laser to create channels through the myocardial wall to the ventricular chamber. Although there is controversy about the mechanism of action, early clinical trials of TMR in the USA with carbon-dioxide lasers showed encouraging results.2, 3, 4, 5 However, these results have been challenged because of high crossover rates and lack of masked assessment of symptoms. A subsequent study that used a carbon-dioxide laser but did not allow for crossover in the study design showed limited clinical benefits in patients with predominantly class III angina.6
We designed the Angina Treatments—Lasers and Normal Therapies in Comparison (ATLANTIC) prospective randomised study to compare TMR with continued medical therapy in patients with medically refractory angina.
Section snippets
Patients
We recruited 337 patients from 16 US centres who were assessed by their treating physician and referred for this study (figure 1). After a medical history was taken, the most recent angiogram reviewed, and informed consent obtained, patients underwent baseline testing. Tests were echocardiography, a dipyridamole thallium stress test, treadmill exercise-tolerance testing (Modified Bruce Protocol), and a self-administered Seattle angina questionnaire. The Seattle angina questionnaire consists of
Results
182 of 337 patients were enrolled (figure 1). The main reasons for exclusion were absence of objective evidence of ischaemia on dipyridamole thallium stress test (34), patient's decision not to participate (23), eligibility for coronary-artery bypass graft or percutaneous transluminal coronary angioplasty decided by the central laboratory (23), insufficient region of protected myocardium (20), absence of angina on exercise testing (20), and left-ventricular ejection fraction of less than 30%
Discussion
All previous studies of TMR have limited selection of patients to those with the most advanced forms of ischaemic heart disease and the worst symptoms, and those ineligible for standard interventions. Our entry criteria were intended to select such patients. Most of our patients had class IV angina and poor exercise tolerance and were in a stable stage of their disease. There was a high frequency of cardiac risk factors, previous myocardial infarctions, multiple previous invasive therapies, and
References (25)
- et al.
New concepts in revascularization of the myocardium
Ann Thorae Surg
(1988) - et al.
Transmyocardial laser revascularization: clinical experience with twelve-month follow-up
J Thorac Cardiovasc Surg
(1996) - et al.
Transmyocardial laser revascularization: operative techniques and clinical results at two years
J Thorac Cardiovasc Surg
(1996) - et al.
Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease
J Thorac Cardiovasc Surg
(1997) - et al.
Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial
Lancet
(1999) - et al.
Factors correlating with risk of mortality following transmyocardial revascularization
J Am Col Cardiol
(1999) - et al.
Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization
J Am Coll Cardiol
(1995) - et al.
Prevention of acute regional ischemia with endocardial laser channels
Ann Thorac Surg
(1993) - et al.
Histologic appearance of transmyocardial laser channels after 4–1/2 weeks
Ann Thorac Surg
(1996) - et al.
Myocardial perfusion through naturally occurring subendocardial channels
J Thorac Cardiovasc Surg
(1997)
Histologic analysis of transmyocarial laser channels: comparison of CO2 and Holmium:YAG lasers
Ann Thorac Surg
Physiology, histology and 2-week morphology of acute transmyocardial laser channels made with a CO2 laser
Ann Thorac Surg
Cited by (289)
Refractory Angina—Unsolved Problem
2020, Cardiology ClinicsImproving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review
2020, Journal of the American College of CardiologyMinimally-invasive device-based approaches for improving cardiac perfusion
2020, Emerging Technologies for Heart Diseases: Volume 2: Treatments for Myocardial Ischemia and ArrhythmiasRefractory angina pectoris: a 20-year (2003–2022) bibliometric analysis
2023, Frontiers in Cardiovascular Medicine
Investigators listed at end of paper